[From fundamental immunology to development of vaccinology].
In the last ten years research in vaccinology has been developed in the world to conceive new vaccine approaches against infections like HIV/AIDS. Jean-Gérard Guillet is a pioneer in the development of new vaccine strategies. From the first results he obtained in the late 80's on the presentation of antigenic peptides to T cells, he axed his work on the study of induction mechanisms of T cell mediated immune responses. The selection of antigenic peptides and the search to enhance antigen immunogenicity led him to elaborate lipopeptides as new vaccine formulae. The efficacy of these preparations was tested in animal models (mouse, macaque) and, thereafter, in humans with clinical trials promoted by the French National Agency for AIDS and viral hepatitis (ANRS). The study of T-cell induced responses in vaccinated volunteers was implemented following the creation of two facilities, an immuno-monitoring platform and the Clinical Investigation Centre Cochin-Pasteur, a structure specialized in vaccinology.
Choppin
Jeannine
J
Département d'Immunologie, Institut Cochin, INSERM U567, CNRS (UMR 8104), Université Paris Descartes, Bâtiment Hardy A, 27 rue du Faubourg Saint-Jacques, Paris, France. choppin@cochin.inserm.fr
D016915:AIDS Vaccines / Q000627:therapeutic use*; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology*; D000486:Allergy and Immunology / Q000639:trends*; D000939:Epitopes / Q000276:immunology; D015658:HIV Infections / Q000276:immunology; D006525:Hepatitis, Viral, Human / Q000276:immunology; D006801:Humans; D008074:Lipoproteins / Q000276:immunology; D010455:Peptides / Q000276:immunology; D014612:Vaccines / Q000627:therapeutic use
D016915:AIDS Vaccines; D000939:Epitopes; D008074:Lipoproteins; D010455:Peptides; D014612:Vaccines